Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Deferred Revenue (2018 - 2025)

Regenxbio has reported Current Deferred Revenue over the past 11 years, most recently at $10.5 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $10.5 million for Q4 2025, up 8988.7% from a year ago — trailing twelve months through Dec 2025 was $10.5 million (up 8988.7% YoY), and the annual figure for FY2025 was $10.5 million, up 8988.7%.
  • Current Deferred Revenue for Q4 2025 was $10.5 million at Regenxbio, down from $13.2 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for RGNX hit a ceiling of $39.9 million in Q1 2025 and a floor of $13000.0 in Q1 2024.
  • Median Current Deferred Revenue over the past 5 years was $3.3 million (2021), compared with a mean of $6.9 million.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 99.01% in 2024 and later skyrocketed 306707.69% in 2025.
  • Regenxbio's Current Deferred Revenue stood at $3.3 million in 2021, then crashed by 45.12% to $1.8 million in 2022, then tumbled by 91.91% to $148000.0 in 2023, then fell by 22.3% to $115000.0 in 2024, then skyrocketed by 8988.7% to $10.5 million in 2025.
  • The last three reported values for Current Deferred Revenue were $10.5 million (Q4 2025), $13.2 million (Q3 2025), and $37.8 million (Q2 2025) per Business Quant data.